Duvelisib, an oral dual PI3K ‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study

American Journal of Hematology,Volume 0, Issue ja, -Not available-.

Source: American Journal of Hematology - August 10, 2018 Category: Hematology Authors: Susan O'Brien , Manish Patel , Brad S. Kahl , Steven M. Horwitz , Francine M. Foss , Pierluigi Porcu , Jeffrey Jones , Jan Burger , Nitin Jain , Kerstin Allen , Kerrie Faia , Mark Douglas , Howard M. Stern Source Type: research